Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| nef Gene Products, Human Immunodeficiency Virus | 4 | 2021 | 51 | 2.660 |
Why?
|
| Astrocytes | 8 | 2021 | 203 | 2.020 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 13 | 2013 | 55 | 1.870 |
Why?
|
| Simian immunodeficiency virus | 13 | 2013 | 56 | 1.590 |
Why?
|
| Blood-Brain Barrier | 2 | 2021 | 153 | 1.390 |
Why?
|
| Morphine Dependence | 9 | 2010 | 25 | 1.360 |
Why?
|
| Hippocampus | 3 | 2019 | 546 | 1.280 |
Why?
|
| Evolution, Molecular | 8 | 2009 | 249 | 1.170 |
Why?
|
| Memory Disorders | 2 | 2014 | 65 | 0.890 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2021 | 50 | 0.830 |
Why?
|
| Neurons | 3 | 2019 | 1130 | 0.790 |
Why?
|
| Chemokine CCL2 | 2 | 2019 | 82 | 0.780 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 11 | 0.730 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 3 | 2014 | 7 | 0.700 |
Why?
|
| Brain | 4 | 2021 | 1268 | 0.650 |
Why?
|
| HIV-1 | 9 | 2021 | 678 | 0.650 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2021 | 1534 | 0.580 |
Why?
|
| Genes, tat | 2 | 2006 | 8 | 0.570 |
Why?
|
| Disease Progression | 10 | 2013 | 580 | 0.520 |
Why?
|
| Cells, Cultured | 4 | 2021 | 1442 | 0.510 |
Why?
|
| Macaca mulatta | 7 | 2013 | 122 | 0.510 |
Why?
|
| Macaca | 6 | 2009 | 38 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2009 | 214 | 0.460 |
Why?
|
| Animals | 21 | 2021 | 14307 | 0.450 |
Why?
|
| Synapses | 1 | 2014 | 173 | 0.440 |
Why?
|
| Gene Products, vpr | 2 | 2013 | 5 | 0.420 |
Why?
|
| Rats | 4 | 2021 | 3261 | 0.410 |
Why?
|
| Lac Operon | 3 | 2000 | 19 | 0.400 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 66 | 0.380 |
Why?
|
| DNA-Directed RNA Polymerases | 3 | 2000 | 25 | 0.370 |
Why?
|
| Biomedical Research | 3 | 2021 | 371 | 0.360 |
Why?
|
| Narcotics | 1 | 2008 | 28 | 0.330 |
Why?
|
| Molecular Sequence Data | 10 | 2009 | 1490 | 0.330 |
Why?
|
| Primates | 1 | 2008 | 36 | 0.330 |
Why?
|
| Immune System | 1 | 2008 | 40 | 0.330 |
Why?
|
| Disease Models, Animal | 7 | 2014 | 1300 | 0.320 |
Why?
|
| Phylogeny | 4 | 2006 | 612 | 0.320 |
Why?
|
| Male | 12 | 2021 | 18870 | 0.320 |
Why?
|
| Transcription, Genetic | 3 | 2000 | 550 | 0.320 |
Why?
|
| Virus Replication | 2 | 2005 | 261 | 0.300 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2013 | 52 | 0.290 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2006 | 8 | 0.290 |
Why?
|
| Cerebrospinal Fluid | 1 | 2006 | 18 | 0.290 |
Why?
|
| Esophagitis | 1 | 2006 | 4 | 0.290 |
Why?
|
| Eosinophilia | 1 | 2006 | 16 | 0.280 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 29 | 0.280 |
Why?
|
| Gene Products, env | 3 | 2012 | 23 | 0.280 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2006 | 123 | 0.260 |
Why?
|
| Minority Groups | 2 | 2021 | 537 | 0.260 |
Why?
|
| Morphine | 3 | 2013 | 80 | 0.260 |
Why?
|
| Gene Products, pol | 1 | 2003 | 2 | 0.250 |
Why?
|
| Transfection | 3 | 2014 | 496 | 0.240 |
Why?
|
| Chemokine CCL5 | 2 | 2013 | 38 | 0.240 |
Why?
|
| Macrophages | 2 | 2019 | 431 | 0.220 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 200 | 0.220 |
Why?
|
| HIV Infections | 5 | 2012 | 2207 | 0.220 |
Why?
|
| Students | 2 | 2018 | 452 | 0.210 |
Why?
|
| Propranolol | 1 | 2021 | 17 | 0.210 |
Why?
|
| Intestine, Small | 1 | 2021 | 24 | 0.210 |
Why?
|
| Amino Acid Sequence | 5 | 2009 | 1124 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 2 | 2000 | 484 | 0.190 |
Why?
|
| Pteridines | 1 | 2019 | 2 | 0.190 |
Why?
|
| Viral Envelope Proteins | 2 | 2012 | 77 | 0.190 |
Why?
|
| Mutation, Missense | 2 | 2013 | 80 | 0.180 |
Why?
|
| Drug Resistance, Viral | 3 | 2004 | 60 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2013 | 306 | 0.180 |
Why?
|
| Coculture Techniques | 1 | 2019 | 96 | 0.180 |
Why?
|
| Down-Regulation | 1 | 2021 | 420 | 0.180 |
Why?
|
| Cyclic AMP Receptor Protein | 1 | 1998 | 1 | 0.170 |
Why?
|
| Opioid-Related Disorders | 2 | 2013 | 112 | 0.170 |
Why?
|
| Lung | 1 | 2021 | 413 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1152 | 0.170 |
Why?
|
| Physiology | 1 | 2018 | 14 | 0.170 |
Why?
|
| Escherichia coli | 2 | 1998 | 436 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Thinking | 1 | 2018 | 35 | 0.160 |
Why?
|
| Professional Role | 1 | 2018 | 38 | 0.160 |
Why?
|
| Teaching | 1 | 2018 | 51 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 104 | 0.160 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1998 | 145 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 4 | 2009 | 455 | 0.150 |
Why?
|
| HIV | 2 | 2007 | 97 | 0.140 |
Why?
|
| AIDS Dementia Complex | 2 | 2014 | 107 | 0.140 |
Why?
|
| Humans | 15 | 2021 | 34853 | 0.130 |
Why?
|
| Synaptophysin | 1 | 2014 | 6 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2015 | 80 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 19 | 0.120 |
Why?
|
| Space Perception | 1 | 2014 | 31 | 0.120 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2013 | 24 | 0.120 |
Why?
|
| Maze Learning | 1 | 2014 | 100 | 0.120 |
Why?
|
| Janus Kinases | 1 | 2013 | 19 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 33 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 93 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2014 | 115 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 90 | 0.120 |
Why?
|
| Brain Tissue Transplantation | 1 | 2012 | 3 | 0.110 |
Why?
|
| Viral Load | 4 | 2007 | 300 | 0.110 |
Why?
|
| Virulence Factors | 1 | 2013 | 113 | 0.110 |
Why?
|
| Endogenous Retroviruses | 1 | 2012 | 16 | 0.110 |
Why?
|
| Virus Activation | 1 | 2012 | 35 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 162 | 0.110 |
Why?
|
| Mutation | 3 | 2009 | 1023 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 245 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2007 | 185 | 0.100 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2012 | 108 | 0.100 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2011 | 54 | 0.100 |
Why?
|
| Interleukin-18 | 1 | 2010 | 13 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 14 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2011 | 140 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2010 | 46 | 0.100 |
Why?
|
| Anti-HIV Agents | 2 | 2004 | 394 | 0.090 |
Why?
|
| Sequence Alignment | 3 | 2009 | 257 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 859 | 0.090 |
Why?
|
| Motor Activity | 1 | 2012 | 393 | 0.090 |
Why?
|
| Retroviridae Proteins | 1 | 2009 | 7 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 391 | 0.090 |
Why?
|
| Research Personnel | 2 | 2021 | 133 | 0.080 |
Why?
|
| Female | 5 | 2021 | 19873 | 0.080 |
Why?
|
| Oxidants | 1 | 2007 | 43 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2006 | 328 | 0.080 |
Why?
|
| Reassortant Viruses | 1 | 2006 | 10 | 0.070 |
Why?
|
| Models, Animal | 1 | 2006 | 131 | 0.070 |
Why?
|
| Point Mutation | 1 | 2006 | 88 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2006 | 111 | 0.070 |
Why?
|
| Gene Products, tat | 1 | 2005 | 34 | 0.070 |
Why?
|
| Amino Acids | 1 | 2006 | 139 | 0.070 |
Why?
|
| Retroviruses, Simian | 1 | 2005 | 3 | 0.070 |
Why?
|
| Exons | 1 | 2005 | 80 | 0.070 |
Why?
|
| Anxiety | 1 | 2012 | 705 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 211 | 0.070 |
Why?
|
| Puerto Rico | 2 | 2015 | 1352 | 0.070 |
Why?
|
| Child | 2 | 2018 | 2875 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 386 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2003 | 104 | 0.060 |
Why?
|
| Alcoholism | 1 | 2005 | 220 | 0.050 |
Why?
|
| United States | 2 | 2019 | 3894 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2007 | 874 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Alkylation | 1 | 2000 | 11 | 0.050 |
Why?
|
| Hydroxyl Radical | 1 | 2000 | 15 | 0.050 |
Why?
|
| Base Sequence | 2 | 1998 | 932 | 0.040 |
Why?
|
| RNA, Viral | 3 | 2005 | 287 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Job Description | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Line | 2 | 2013 | 1289 | 0.040 |
Why?
|
| Models, Educational | 1 | 2018 | 41 | 0.040 |
Why?
|
| Binding Sites | 1 | 2000 | 597 | 0.040 |
Why?
|
| Career Choice | 1 | 2018 | 44 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 605 | 0.040 |
Why?
|
| Protein Folding | 1 | 1998 | 121 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Protein Binding | 1 | 2000 | 913 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 316 | 0.040 |
Why?
|
| Curriculum | 1 | 2018 | 237 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 1997 | 125 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2015 | 9 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 26 | 0.030 |
Why?
|
| Genes, pol | 2 | 2004 | 15 | 0.030 |
Why?
|
| HIV Protease | 2 | 2004 | 21 | 0.030 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2004 | 33 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 167 | 0.030 |
Why?
|
| Vagina | 2 | 2004 | 81 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 583 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2012 | 72 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 38 | 0.030 |
Why?
|
| Fetus | 1 | 2011 | 103 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 485 | 0.020 |
Why?
|
| Genes, env | 1 | 2009 | 13 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 2009 | 25 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2009 | 134 | 0.020 |
Why?
|
| Adult | 3 | 2015 | 11034 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 165 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2007 | 38 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 641 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 650 | 0.020 |
Why?
|
| Catalase | 1 | 2007 | 106 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 149 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2005 | 28 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 1802 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4012 | 0.020 |
Why?
|
| Candidiasis, Oral | 1 | 2004 | 23 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 150 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 41 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2004 | 62 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 29 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 122 | 0.020 |
Why?
|
| Epitopes | 1 | 2004 | 145 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2004 | 67 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 251 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 219 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 5668 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 295 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 9642 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1681 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 34 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1997 | 87 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 184 | 0.010 |
Why?
|